Conformetrix signs AstraZeneca deal

CONFORMETRIX has signed a two-year collaboration deal with pharma giant AstraZeneca.

The spin-out company’s proprietary technology will be applied by Astrazeneca across its early-stage drug portfolio to identify which compounds are likely to be successes.

Conformetrix’s technology analyses drug molecules to discover how they are likely to react with their targets.

The deal with Astrazeneca involves the Anglo-Swiss drugs giant providing an undisclosed upfront payment as well as paying for further research once certain milestones are met.

The company’s CEO Dr Sam Williams, said: “Conformetrix is delighted that its first collaborative deal is with AstraZeneca, a company with a strong reputation in innovative science-led R&D.

“We believe that this deal provides important validation of our technology, which improves the quality and efficiency of drug discovery, reducing the number of molecules needed to find a drug and enhancing the likelihood of clinical success.”

Mike Snowden, vice-president and head of discovery sciences at AstraZeneca, said: “We are excited to be working with Conformetrix.

“We believe their technology will provide a powerful addition to our hit identification and lead optimisation approaches, supporting our strategic objectives to improve the quality and choice of candidate compounds for our early pipeline.”

Close